Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History AUTL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics AUTL

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Autolus Therapeutics Ltd

AUTL
Current price
2.42 USD -0.04 USD (-1.63%)
Last closed 2.49 USD
ISIN US05280R1005
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 649 376 704 USD
Yield for 12 month -44.37 %
1Y
3Y
5Y
10Y
15Y
AUTL
21.11.2021 - 28.11.2021

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom. Address: The Mediaworks, London, United Kingdom, W12 7FP

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

9.86 USD

P/E Ratio

Dividend Yield

Financials AUTL

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures AUTL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+10 120 000 USD

Last Year

+1 698 000 USD

Current Quarter

+8 982 000 USD

Last Quarter

+29 000 USD

Current Year

-1 267 000 USD

Last Year

-4 867 000 USD

Current Quarter

-8 969 000 USD

Last Quarter

-13 435 000 USD
EBITDA -259 082 000 USD
Operating Margin TTM -726.31 %
Price to Earnings
Return On Assets TTM -20.28 %
PEG Ratio
Return On Equity TTM -49.97 %
Wall Street Target Price 9.86 USD
Revenue TTM 9 011 000 USD
Book Value 1.39 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -11.00 %
Dividend Yield
Gross Profit TTM -146 023 008 USD
Earnings per share -0.88 USD
Diluted Eps TTM -0.88 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation AUTL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 27.34
Price Sales TTM 72.06
Enterprise Value EBITDA 0.033
Price Book MRQ 1.79

Technical Indicators AUTL

For 52 Weeks

1.11 USD 5.00 USD
50 Day MA 1.91 USD
Shares Short Prior Month 12 714 466
200 Day MA 2.40 USD
Short Ratio 5.19
Shares Short 13 670 391
Short Percent 6.29 %